Why is the Polynovo (ASX:PNV) share price having such a tough time of late?

What's up with medical device company's shares? We take a closer look

The Polynovo Ltd (ASX: PNV) share price has been on a trending decline over the past 6 months, falling by 40%. This comes as the medical device company has been relatively quiet on the news front.

At Tuesday's closing bell, Polynovo shares finished the day up 3.61% to $1.865.

A doctor in a white coat with a stethoscope around her neck holds her hands upwards as if to ask 'why' as she sits at her desk and looks at her computer.

Image source: Getty Images

What's been happening with Polynovo lately?

While no new announcements have been released since last month, Polynovo has been busy progressing its BARDA-funded burn study. BARDA is an acronym for the United States-based Biomedical Advanced Research and Development Authority.

The trial spans 20 United States and 5 Canadian burn centres for the clinical study of NovoSorb BTM. Polynovo aims for its NovoSorb BTM to be used as a standard of care in burn patients.

In addition, the company's chief operating officer, Dr Anthony Kaye, resigned from his position last month. The Polynovo share price fell more than 10% that week after it was revealed Dr Kaye was returning to CSL Limited (ASX: CSL) in a more senior role.

However, Polynovo's path to profitability is growing stronger following its robust FY21 results.

The company experienced growth across key financial metrics which led it to break even for the first time in its history.

Polynovo expects continued momentum to run into FY22 across a number of geographical markets. These include the United States, Europe, the United Kingdom, the Middle East, Asia, Australia, and New Zealand.

Its NovoSorb graft is expected to see sales surge in FY22, with "70% of burns centres now having purchased" the product.

Furthermore, Polynovo intends to expand its headcount and enter new markets, particularly within the European Union.

Nonetheless, the Polynovo share price has slumped. This is possibly due to bearish sentiment by investors which has caused selling pressure.

Polynovo share price summary

Despite today's gain, Polynovo shares are down more than 25% for the past 12 months, and 50% in 2021.

Polynovo has a market capitalisation of roughly $1.24 billion and has approximately 661.4 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »